Journal of the American Heart Association
-
Randomized Controlled Trial Multicenter Study
Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER.
Clinical trials traditionally use time-to-first-event analysis embedded within the composite endpoint of cardiovascular death (CVD), myocardial infarction (MI), or stroke. However, many patients have >1 event, and this approach may not reflect overall experience. We addressed this by analyzing all cardiovascular events in TRACER. ⋯ ClinicalTrials.gov. Unique identifier: NCT00527943.